Rapid Dose Therapeutics welcomes Peter Thilo Hasler to its Board of Directors

– CANADA, Burlington –  Rapid Dose Therapeutics Corp. (CSE: DOSE) trading on the Canadian Securities Exchange, today announced the appointment of Peter Thilo Hasler to the board of directors.

“We are excited to welcome Peter to our board of directors and assuming an important role as an independent member of the audit committee. He brings decades of leadership in key financial areas, an in-depth understanding of the European investment community, and a broad network of German institutional equity and bond investors, family offices, and asset managers.” said CEO, Mark Upsdell.

RDT’s announcement yesterday of its credit facility financing provides RDT with the resources to exploit opportunities in the European market for its nutraceutical products, cannabis, and pharmaceutical lines. Hasler’s appointment to the board provides RDT with European market access to financial and business relationships to facilitate and support RDT’s entry into the European market.

About Peter Thilo Hasler

Peter Thilo Hasler is the founder and financial analyst of Sphene Capital, a bank-independent research house specializing in the analysis of undervalued small and mid-cap companies, both listed and private. Hasler has a comprehensive knowledge of business analysis and company valuation and was responsible for numerous IPO transactions. Since the foundation of sphaia advisory GmbH in 2015, Hasler offers corporate finance, listing, and communications advice to European SMEs too.

Peter Thilo Hasler is CEFA analyst and member of the board of the German Association for Financial Analysis and Asset Management. In addition, Hasler is a lecturer at the DVFA and at several private universities, where he teaches company valuation and capital markets theory. Hasler is author of numerous articles and books on business valuation as well as corporate bonds and writes regular columns in the financial press. Peter Thilo Hasler is married and has two sons.

About Rapid Dose Therapeutics

Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key business solution which enables RDT’s QuickStrip proprietary drug delivery technology to be licensed by select partners. RDT’s service-based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. RDT is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs — including humans, animals, and plants.

For more information: https://www.rapid-dose.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>